Nasdaq Fold News Today

Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report) has earned a consensus rating of “Moderate Buy” from the five brokerages that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1-year target price among analysts […]

Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) – Zacks Research decreased their Q3 2024 earnings estimates for shares of Amicus Therapeutics in a report issued on Thursday, January 18th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will earn $0.00 per share for the quarter, down from their prior estimate of $0.01. […]

Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) – Equities researchers at Zacks Research lowered their Q3 2024 EPS estimates for Amicus Therapeutics in a research note issued to investors on Thursday, January 18th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will earn $0.00 per share for the quarter, down from their […]

Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report) insider David Michael Clark sold 1,384 shares of Amicus Therapeutics stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $14.00, for a total value of $19,376.00. Following the completion of the sale, the insider now owns 266,705 shares of […]

2023 Total Revenue of ~$399.4M, a 21% Increase Year-Over-Year >2,400 People Living with Fabry Disease on Galafold® Following a Year of Increased Demand...

Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report) CEO Bradley L. Campbell sold 15,833 shares of the business’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $14.23, for a total transaction of $225,303.59. Following the transaction, the chief executive officer now owns 947,805 shares of the […]

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report) have been given an average recommendation of “Moderate Buy” by the six ratings firms that are currently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The […]

Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report) has received an average rating of “Moderate Buy” from the six analysts that are covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1-year price target among […]

Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report) Chairman John F. Crowley sold 6,043 shares of the company’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $11.08, for a total transaction of $66,956.44. Following the completion of the sale, the chairman now directly owns 883,791 shares […]

Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report) Chairman John F. Crowley sold 6,043 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $11.08, for a total transaction of $66,956.44. Following the completion of the transaction, the chairman now directly owns […]